Zanzalintinib for advanced pheochromocytoma and paraganglioma
Treatments studied
Part of Cancer clinical trials.
This trial tests a new oral medication called zanzalintinib for adults with a rare type of tumor called pheochromocytoma or paraganglioma that has spread or cannot be removed with surgery. The goal is to see if this drug can slow or stop the tumor from growing, and to evaluate its safety.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have been diagnosed with pheochromocytoma or paraganglioma that has spread (metastatic) or cannot be surgically removed.
- Your tumor has grown or spread within the last 12 months, as seen on a CT or MRI scan.
- You are able to take care of yourself (ECOG performance status 0-2) and have adequate organ function (kidney, liver, blood counts).
- You have not had certain treatments within the last 3-6 weeks (like chemotherapy, radiation, or other investigational drugs) before starting the study.
- You must agree to use two effective methods of birth control if you or your partner can have children, and not be pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests two targeted drugs, anlotinib and benmelstobart, for people with advanced pheochromocytoma or paraganglioma that has spread or come back after treatment. These drugs may help shrink tumors or slow their growth.
This study tests a new oral medication called zanzalitinib, which may help slow the growth of advanced prostate cancer that has continued to spread despite hormone therapy and possibly chemotherapy. The goal is to see if the drug is safe and effective for men with this type of cancer.
This trial tests a new drug called zanzalintinib for people with advanced or metastatic bone sarcomas that have not responded to standard treatments. It aims to see if the drug can help shrink or slow the growth of these tumors.
This trial tests a new drug, zanzalintinib, for people with adenoid cystic carcinoma that has come back or spread and can't be treated with local therapy. The drug may help slow or stop the cancer's growth.
This trial tests a new targeted therapy pill (XL092, also called zanzalintinib) for people with certain advanced sarcomas that have not responded to other treatments. The goal is to see if the drug shrinks tumors or slows their growth.
This trial tests a new drug, zanzalintinib, in men with a fast-growing type of prostate cancer that has spread and stopped responding to standard hormone therapies. It aims to see if the drug can help shrink tumors or slow the disease.
Hear when a new Pheochromocytoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.